343 related articles for article (PubMed ID: 12173038)
1. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation.
Morrison KB; Tognon CE; Garnett MJ; Deal C; Sorensen PH
Oncogene; 2002 Aug; 21(37):5684-95. PubMed ID: 12173038
[TBL] [Abstract][Full Text] [Related]
2. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation.
Tognon C; Garnett M; Kenward E; Kay R; Morrison K; Sorensen PH
Cancer Res; 2001 Dec; 61(24):8909-16. PubMed ID: 11751416
[TBL] [Abstract][Full Text] [Related]
3. A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.
Lannon CL; Martin MJ; Tognon CE; Jin W; Kim SJ; Sorensen PH
J Biol Chem; 2004 Feb; 279(8):6225-34. PubMed ID: 14668342
[TBL] [Abstract][Full Text] [Related]
4. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.
Martin MJ; Melnyk N; Pollard M; Bowden M; Leong H; Podor TJ; Gleave M; Sorensen PH
Mol Cell Biol; 2006 Mar; 26(5):1754-69. PubMed ID: 16478996
[TBL] [Abstract][Full Text] [Related]
5. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
[TBL] [Abstract][Full Text] [Related]
6. Increased insulin sensitivity in IGF-I receptor--deficient brown adipocytes.
Mur C; Valverde AM; Kahn CR; Benito M
Diabetes; 2002 Mar; 51(3):743-54. PubMed ID: 11872675
[TBL] [Abstract][Full Text] [Related]
7. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
Jin W; Yun C; Hobbie A; Martin MJ; Sorensen PH; Kim SJ
Cancer Res; 2007 Apr; 67(7):3192-200. PubMed ID: 17409427
[TBL] [Abstract][Full Text] [Related]
8. ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages.
Lannon CL; Sorensen PH
Semin Cancer Biol; 2005 Jun; 15(3):215-23. PubMed ID: 15826836
[TBL] [Abstract][Full Text] [Related]
9. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma.
Knezevich SR; Garnett MJ; Pysher TJ; Beckwith JB; Grundy PE; Sorensen PH
Cancer Res; 1998 Nov; 58(22):5046-8. PubMed ID: 9823307
[TBL] [Abstract][Full Text] [Related]
10. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
11. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.
Rubin BP; Chen CJ; Morgan TW; Xiao S; Grier HE; Kozakewich HP; Perez-Atayde AR; Fletcher JA
Am J Pathol; 1998 Nov; 153(5):1451-8. PubMed ID: 9811336
[TBL] [Abstract][Full Text] [Related]
12. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.
Tognon CE; Martin MJ; Moradian A; Trigo G; Rotblat B; Cheng SW; Pollard M; Uy E; Chow C; Carboni JM; Gottardis MM; Pollak M; Morin GB; Sorensen PH
Oncogene; 2012 Mar; 31(10):1334-40. PubMed ID: 21804605
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine phosphorylation-dependent and -independent role of Shc in the regulation of IGF-1-induced mitogenesis and glycogen synthesis.
Sasaoka T; Ishiki M; Wada T; Hori H; Hirai H; Haruta T; Ishihara H; Kobayashi M
Endocrinology; 2001 Dec; 142(12):5226-35. PubMed ID: 11713219
[TBL] [Abstract][Full Text] [Related]
14. Interferon-dependent activation of the serine kinase PI 3'-kinase requires engagement of the IRS pathway but not the Stat pathway.
Uddin S; Majchrzak B; Wang PC; Modi S; Khan MK; Fish EN; Platanias LC
Biochem Biophys Res Commun; 2000 Apr; 270(1):158-62. PubMed ID: 10733921
[TBL] [Abstract][Full Text] [Related]
15. Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival.
Zheng WH; Quirion R
J Neurochem; 2004 May; 89(4):844-52. PubMed ID: 15140184
[TBL] [Abstract][Full Text] [Related]
16. Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter.
Nyga R; Pecquet C; Harir N; Gu H; Dhennin-Duthille I; Régnier A; Gouilleux-Gruart V; Lassoued K; Gouilleux F
Biochem J; 2005 Aug; 390(Pt 1):359-66. PubMed ID: 15833084
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediated mitogenic signalling.
Cousin SP; Hügl SR; Myers MG; White MF; Reifel-Miller A; Rhodes CJ
Biochem J; 1999 Dec; 344 Pt 3(Pt 3):649-58. PubMed ID: 10585851
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals.
Esposito DL; Blakesley VA; Koval AP; Scrimgeour AG; LeRoith D
Endocrinology; 1997 Jul; 138(7):2979-88. PubMed ID: 9202243
[TBL] [Abstract][Full Text] [Related]
19. Insulin receptor substrate-1 enhances growth hormone-induced proliferation.
Liang L; Zhou T; Jiang J; Pierce JH; Gustafson TA; Frank SJ
Endocrinology; 1999 May; 140(5):1972-83. PubMed ID: 10218944
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells.
Kim B; Leventhal PS; White MF; Feldman EL
Endocrinology; 1998 Dec; 139(12):4881-9. PubMed ID: 9832424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
